{
  "kind": "all",
  "value": "all",
  "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations",
  "filters": {
    "documentKinds": [],
    "sourceTypes": [],
    "orientations": []
  },
  "total": 319975,
  "page": 7220,
  "pageSize": 30,
  "pageCount": 10666,
  "rows": [
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 102,
      "slideType": "key_takeaways",
      "function": "analyze_data",
      "notes": "Includes a Kaplan-Meier survival curve and a biological diagram of TLS.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/102",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-102",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 103,
      "slideType": "propose_solution",
      "function": "present_solution",
      "notes": "The slide outlines a proprietary R&D workflow for antibody discovery.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/103",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-103",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 104,
      "slideType": "section_divider",
      "function": "transition",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/104",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-104",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 105,
      "slideType": "other",
      "function": "illustrate_case",
      "notes": "The slide illustrates a scientific workflow for target discovery.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/105",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-105",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 106,
      "slideType": "propose_solution",
      "function": "present_solution",
      "notes": "The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/106",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-106",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 107,
      "slideType": "market_sizing",
      "function": "size_opportunity",
      "notes": "The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/107",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-107",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 108,
      "slideType": "roadmap",
      "function": "present_solution",
      "notes": "The chart uses a horizontal bar format to represent development progress against a timeline of stages (Target Eval to IND).",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/108",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-108",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 109,
      "slideType": "closing_ask",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/109",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-109",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 111,
          "from": 109,
          "beatId": "e6b2e023-8998-45e3-8419-81aaa960723a",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "The presentation concludes with a call to action and a final thought, leaving the audience with a sense of satisfaction.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 110,
      "slideType": "closing_ask",
      "function": "state_next_steps",
      "notes": "The slide uses code snippets as decorative background elements.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/110",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-110",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 111,
          "from": 109,
          "beatId": "e6b2e023-8998-45e3-8419-81aaa960723a",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "The presentation concludes with a call to action and a final thought, leaving the audience with a sense of satisfaction.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e061-72f9-baa2-90171b05eced",
      "docSlug": "cdaaa50efb264b4a4093f665bafb20a4",
      "documentTitle": "Absci | Investor Presentation Deck | 111 slides",
      "authorId": "absci",
      "authorName": "Absci",
      "documentKindSlug": "conference-presentation",
      "documentKindLabel": "Conference presentation",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 111,
      "slideType": "closing_ask",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e061-72f9-baa2-90171b05eced/111",
      "deckHref": "/decks/019de075-e061-72f9-baa2-90171b05eced",
      "deckAnchorHref": "/decks/019de075-e061-72f9-baa2-90171b05eced#slide-111",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 111,
          "from": 109,
          "beatId": "e6b2e023-8998-45e3-8419-81aaa960723a",
          "arcName": "The Sparkline",
          "arcSlug": "sparkline",
          "beatName": "Satisfaction",
          "beatSlug": "monroes-sequence-satisfaction",
          "evidence": "The presentation concludes with a call to action and a final thought, leaving the audience with a sense of satisfaction.",
          "position": 4,
          "confidence": 0.8,
          "parentBeatName": "Turn",
          "parentBeatSlug": "turn"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 1,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "The slide features a split design with a white left side containing logos and a dark purple abstract background on the right.",
      "imagePath": "https://imgproxy.kitesheet.com/0DmB7O5C1luLQ2ukdFPCMIoqJcEu2HQU_Tb3M9RspD4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ODE5ZjM1MTJlNTY1YjkxOGM2Y2ZjOGUzNjg4Y2ZiMi9wMDAxLmpwZw",
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/1",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-1",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": "https://imgproxy.kitesheet.com/UHkw1DJhbHDgJIqg-Fv5IYzvFoWMTcSflMfdJvpS9GY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ODE5ZjM1MTJlNTY1YjkxOGM2Y2ZjOGUzNjg4Y2ZiMi9wMDAxLnBuZw",
      "thumbSrc": "https://imgproxy.kitesheet.com/c6S8btX99JzENyx6g-D_GENXc713KzbVV1dkPlj6DrE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ODE5ZjM1MTJlNTY1YjkxOGM2Y2ZjOGUzNjg4Y2ZiMi9wMDAxLmpwZw",
      "thumbSrcAlt": "https://imgproxy.kitesheet.com/WKm9GRKQrQujzlpqlsc-kxBEbH3_llPpWGlGA1b_IPY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy85ODE5ZjM1MTJlNTY1YjkxOGM2Y2ZjOGUzNjg4Y2ZiMi9wMDAxLnBuZw"
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 2,
      "slideType": "appendix_disclosure",
      "function": "other",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/2",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-2",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 3,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The slide uses a Gantt-style chart to show the development stage of multiple drug programs.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/3",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-3",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 3,
          "beatId": "9e92e950-6d7d-4a39-aa35-77037b50a0b7",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Targeting new heights in the treatment of IBD, Potential best-in-class lead programs",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 4,
      "slideType": "product_demo",
      "function": "present_solution",
      "notes": "The slide uses a three-column layout to compare product candidates.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/4",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-4",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 4,
          "from": 3,
          "beatId": "9e92e950-6d7d-4a39-aa35-77037b50a0b7",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Situation & Context",
          "beatSlug": "consultants-gambit-situation-context",
          "evidence": "Targeting new heights in the treatment of IBD, Potential best-in-class lead programs",
          "position": 2,
          "confidence": 0.8,
          "parentBeatName": "Setup",
          "parentBeatSlug": "setup"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 5,
      "slideType": "problem_statement",
      "function": "frame_problem",
      "notes": "The chart is a scatter plot showing maintenance remission rates vs. dosing frequency, positioning current therapies in a cluster and the company's target in a superior quadrant.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/5",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-5",
      "loopMatches": [
        {
          "to": 6,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1e678675-b00f-4ca4-9628-1ea0d4fbdd6f",
          "evidence": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
          "position": 0,
          "objective": "What are the consequences of not addressing unmet needs in IBD?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 5,
          "from": 5,
          "beatId": "d3d060f4-a6ef-45ba-9081-b2065408160d",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Problem",
          "beatSlug": "problem-agitate-solution-problem-identify-pain",
          "evidence": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
          "position": 0,
          "confidence": 0.8,
          "parentBeatName": "Complication",
          "parentBeatSlug": "complication"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 6,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "The slide uses a three-column layout to present the company's core technological approaches.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/6",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-6",
      "loopMatches": [
        {
          "to": 6,
          "from": 5,
          "name": "Cost Of Inaction",
          "slug": "27-cost-of-inaction",
          "bestFor": "Urgent budget requests, compliance, risk mitigation",
          "matchId": "1e678675-b00f-4ca4-9628-1ea0d4fbdd6f",
          "evidence": "Despite advances, new approaches are needed to break the efficacy ceiling and improve convenience of biologics",
          "position": 0,
          "objective": "What are the consequences of not addressing unmet needs in IBD?",
          "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
          "confidence": 0.7,
          "description": "Quantify what happens if the audience does nothing"
        }
      ],
      "arcBeatMatches": [
        {
          "to": 6,
          "from": 6,
          "beatId": "08639147-5bfb-445c-a16c-e908eaca73ea",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Solution",
          "beatSlug": "problem-agitate-solution-solution-provide-relief",
          "evidence": "Our strategy is built on three validated approaches to address unmet needs in IBD",
          "position": 1,
          "confidence": 0.8,
          "parentBeatName": "Resolution",
          "parentBeatSlug": "resolution"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 7,
      "slideType": "roadmap",
      "function": "plan_implementation",
      "notes": "The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/7",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-7",
      "loopMatches": [
        {
          "to": 8,
          "from": 7,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "f1b337db-6c6a-4ce5-ac0d-8b7da161a10f",
          "evidence": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "position": 1,
          "objective": "Can Spyre Therapeutics' pipeline deliver a best-in-class IBD treatment?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 8,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "The slide uses a split-screen layout with a photo of a person on the right and branding on the left.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/8",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-8",
      "loopMatches": [
        {
          "to": 8,
          "from": 7,
          "name": "Quick Win Big Bet",
          "slug": "47-quick-win-big-bet",
          "bestFor": "Transformation planning, 100-day plans, resource allocation",
          "matchId": "f1b337db-6c6a-4ce5-ac0d-8b7da161a10f",
          "evidence": "Spyre is building a potentially best-in-class IBD pipeline with next-generation mAbs and rational combinations",
          "position": 1,
          "objective": "Can Spyre Therapeutics' pipeline deliver a best-in-class IBD treatment?",
          "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
          "confidence": 0.7,
          "description": "Separate initiatives into immediate wins and longer-term strategic bets"
        }
      ],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 9,
      "slideType": "solution",
      "function": "present_solution",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/9",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-9",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 11,
          "from": 9,
          "beatId": "4a654b29-f8fd-4689-809f-c704cc8af64b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "SPY001 potency & selectivity matches vedolizumab, SPY001 has exhibited ~2x the half-life of vedolizumab in NHPs",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 10,
      "slideType": "solution",
      "function": "present_solution",
      "notes": "Includes structural biology visualization, dose-response curves, and a binding affinity table.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/10",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-10",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 11,
          "from": 9,
          "beatId": "4a654b29-f8fd-4689-809f-c704cc8af64b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "SPY001 potency & selectivity matches vedolizumab, SPY001 has exhibited ~2x the half-life of vedolizumab in NHPs",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 11,
      "slideType": "traction",
      "function": "show_traction",
      "notes": "Pharmacokinetic study results showing extended half-life for the drug candidate.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/11",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-11",
      "loopMatches": [],
      "arcBeatMatches": [
        {
          "to": 11,
          "from": 9,
          "beatId": "4a654b29-f8fd-4689-809f-c704cc8af64b",
          "arcName": "Problem-Agitate-Solution",
          "arcSlug": "problem-agitate-solution",
          "beatName": "Evidence & Proof",
          "beatSlug": "consultants-gambit-evidence-proof",
          "evidence": "SPY001 potency & selectivity matches vedolizumab, SPY001 has exhibited ~2x the half-life of vedolizumab in NHPs",
          "position": 3,
          "confidence": 0.8,
          "parentBeatName": "Evidence",
          "parentBeatSlug": "evidence"
        }
      ],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 12,
      "slideType": "appendix_methodology",
      "function": "present_framework",
      "notes": "The slide outlines a standard clinical trial progression for SAD and MAD cohorts, including randomization ratios and participant types.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/12",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-12",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 13,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/13",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-13",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 14,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "Includes PK modeling data comparing human and NHP half-lives and steady-state concentration simulations.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/14",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-14",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 15,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "Uses icon-based visualization to represent injection frequency.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/15",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-15",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 16,
      "slideType": "appendix_data",
      "function": "analyze_data",
      "notes": "The slide uses a bar chart to show dose-response correlation and a line chart to show pharmacokinetic modeling.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/16",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-16",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 17,
      "slideType": "comparison_table",
      "function": "compare_peers",
      "notes": "The slide uses a timeline-like visual to compare dosing schedules at weeks 0, 2, and 6.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/17",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-17",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 18,
      "slideType": "competitive_analysis",
      "function": "compare_peers",
      "notes": "The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/18",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-18",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 19,
      "slideType": "key_takeaways",
      "function": "summarize",
      "notes": null,
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/19",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-19",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    },
    {
      "docId": "019de075-e109-770f-8f32-3054686041b6",
      "docSlug": "9819f3512e565b918c6cfc8e3688cfb2",
      "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides",
      "authorId": "aeglea-biotherapeutics",
      "authorName": "Spyre Therapeutics",
      "documentKindSlug": "pitchdeck",
      "documentKindLabel": "Pitch deck",
      "sourceTypeSlug": "investor_relations",
      "sourceTypeLabel": "Investor relations",
      "presentationDate": "2023-10-01 00:00:00",
      "orientation": "landscape",
      "aspectRatio": 1.7777778,
      "pageNumber": 20,
      "slideType": "cover",
      "function": "front_matter",
      "notes": "Features a stylized antibody icon overlay on a photo of a person.",
      "imagePath": null,
      "matchCount": 1,
      "evidence": null,
      "slideHref": "/slides/019de075-e109-770f-8f32-3054686041b6/20",
      "deckHref": "/decks/019de075-e109-770f-8f32-3054686041b6",
      "deckAnchorHref": "/decks/019de075-e109-770f-8f32-3054686041b6#slide-20",
      "loopMatches": [],
      "arcBeatMatches": [],
      "imagePathAlt": null,
      "thumbSrc": null,
      "thumbSrcAlt": null,
      "locked": true
    }
  ]
}